Viatris Raises Guidance and Boosts Capital Returns Amid Ongoing Challenges.

Viatris reported strong Q3 2025 results, raising its full-year guidance to $13.9-14.3 billion in revenue and increasing adjusted EPS. Management emphasized growth through mergers and acquisitions and reaffirmed a commitment to shareholder returns. The upgraded guidance and increased capital returns reinforce the company's investment narrative, but challenges remain, including price erosion in key markets and dependence on mature drugs. The stock's fair value is estimated between $10.47 and $47.25.